Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed/Refractory Aggressive Mature B-cell Neoplasms Receiving Subcutaneous (SC) Injections of Epcoritamab

NCT05206357 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

17

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-hodgkin Lymphoma

Interventions

DRUG: Epcoritamab

Sponsor

Genmab

Collaborators

[object Object]